CVR: 21682977
Previous names: BIOGEN IDEC (DENMARK) A/S
The financial health of BIOGEN (DENMARK) A/S appears to be declining, with a notable decrease in revenue from 307.5 million DKK in 2022 to 234.0 million DKK in 2024. Profit has also decreased, dropping from 8.4 million DKK in 2022 to 7.5 million DKK in 2024, indicating potential challenges in maintaining profitability. However, the company has shown a steady increase in equity, rising from 114.5 million DKK in 2020 to 146.3 million DKK in 2024, which may provide a buffer against financial instability. Despite its declining revenue and profit margins, BIOGEN maintains a position within the medical supply industry, but its current trajectory raises concerns about its long-term sustainability.
AI-generated summary
Selskabets formål er at markedsføre og distribuere lægemidler samt, direkte eller indirekte, at drive anden virksomhed, der efter bestyrelsens skøn er forbunden dermed
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 234 mio. | 7.5 mio. | 191.1 mio. | 146.3 mio. | 22 | |
Compared to 290 companies in Engroshandel med læge- og hospitalsartikler
Comparison is based on industry median values
4 public tenders won
Sources: TED (the EU tender database) and udbud.dk
Erik Magnus Bodin joined the board
Morten Lofthus Tangnes left the board
Erik Magnus Bodin joined as director
Morten Lofthus Tangnes left as director
Companies in the same industry and area
CVR 41344806
CVR 39870665
CVR 41747978
CVR 37231304
CVR 37003204
companydata.dk